Tempus is a health technology company that is collecting and storing data from different organizations to allow clinicians and doctors to devise better treatment plans for their patients especially those who do not respond to conventional treatment plans. It will have algorithms that will assess variations and similarities in different samples to allow doctors to identify patterns and to find out how patients respond to various treatment plans.
The Cofounder and CEO of Tempus, Mr. Eric recently told the news reporter during an interview that he started the company so that he can allow the clinicians access big data related to the different research and increase the effectivity of patient care. He had the idea of creating such a company that will help individuals suffering from cancer and their families to get custom care from their doctors. The company processes genomic sequencing and also offer molecular data that can be used by physicians to find which treatment plan and which drugs will be best for their patients. Eric Lefkofsky on Facebook.
Eric Lefkofsky is a resident of Michigan and has attended some of the best institutions in the country. Even though he was offered jobs with the best companies in the country, he chose to go the entrepreneur way and start something of his own. Today, he is a self-made billionaire and has assets worth over $1.7 billion. When he was young, he started a carpet selling company by borrowing money from his relatives and close friends. Today, he has more than ten established companies under his name, Groupon being among the top.
Even though Eric Lefkofsky can easily stop working and enjoy retirement at an early age, he does not want to stop. After experiencing the need of technology in the health industry, he got the idea of creating Tempus. It has collaborated with many different health institutions and clinical study organizations to collect data and analyze them for the benefit of the patients. His wife has supported him throughout his ups and downs, and both of them even have a foundation through which they help and aid people and organizations with their money and time.
Seattle Genetics focuses on developing innovative antibody-based therapies to treat cancer. The biotechnology company is located in Bothell, Washington. It is the leading producer for antibody-drug conjugates (ADCs). The ADCs technology is designed to help minimize the side effects of chemotherapy since it spares non-targeted cells. The company has built a lusty corporate culture based on teamwork, mutual respect, innovation, scientific excellence and integrity. Seattle Genetics is committed to conducting and performing its business with integrity and professionalism.
The company was co-founded in 1998 by Clay B. Siegall. Clay is currently the company’s Chief Executive Officer, President and Chairman of the Board. Clay Siegall worked with the National Cancer Institute and National Institutes of Health before co-founding Seattle Genetics. Siegall received his Bachelor’s degree from the University of Maryland. He also attended George Washington University where he earned his Ph.D. in Genetics.
Clay Siegall is a specialized in targeted cancer therapies. He led the company in securing the 2011 FDA approval and developing ADCs. The companies first ADC was ADCETRIS (brentuximabvedotin). ADCETRIS is now approved in over 60 countries worldwide. Seattle Genetics has joined many strategic licenses with Abbvie, GlaxoSmithKline and Pfizer and Genentech (Roche).In clinical development, Seattle Genetics’ technology is used by over 20 ADCs. Under the leadership of Clay Siegall, the company has secured more than $1.2 billion via private and public financing.
Seattle genetics is currently trying out Adcetris for cancer treatments. The commercialized drug is being tested against different types of Lymphomas. The company’s CEO announced that Seattle Genetics is conducting an advanced trial that uses Adcetris for the treatment of previously untreated Hodgkin lymphoma. The results of the trials are expected to have a big impact on the company. Adcetris has earned the biotechnology company over $220 million in Canadian and U.S. sales in 2015. Seattle Genetics had its first initial public offering (IPO) in 2001.